Edition:
India

vTv Therapeutics Inc (VTVT.OQ)

VTVT.OQ on NASDAQ Stock Exchange Global Market

5.70USD
19 Jan 2018
Change (% chg)

$0.09 (+1.60%)
Prev Close
$5.61
Open
$5.57
Day's High
$5.86
Day's Low
$5.52
Volume
28,003
Avg. Vol
34,399
52-wk High
$8.04
52-wk Low
$3.63

Latest Key Developments (Source: Significant Developments)

Vtv Therapeutics, Reneo Pharmaceuticals Enter Licensing Agreement
Friday, 22 Dec 2017 

Dec 21 (Reuters) - Vtv Therapeutics Inc ::VTV THERAPEUTICS AND RENEO PHARMACEUTICALS ENTER LICENSING AGREEMENT FOR PPAR-DELTA PROGRAM.VTV THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, VTV THERAPEUTICS WILL RECEIVE AN UPFRONT PAYMENT.VTV THERAPEUTICS INC - UNDER TERMS OF AGREEMENT, VTV THERAPEUTICS WILL ALSO RECEIVE SHARES OF RENEO PHARMACEUTICALS' COMMON STOCK.  Full Article

vTv Therapeutics Signs Agreement With Hangzhou Zhongmei For Rights of Glp-1R Agonist Diabetes Program
Thursday, 21 Dec 2017 

Dec 21 (Reuters) - vTv Therapeutics Inc ::VTV THERAPEUTICS INC SAYS LICENSING AGREEMENT WITH HANGZHOU ZHONGMEI HUADONG PHARMACEUTICAL CO. TO RIGHTS FOR VTV'S GLP-1R AGONIST DIABETES PROGRAM.VTV THERAPEUTICS-GRANTED HUADONG PHARMACEUTICAL EXCLUSIVE LICENSE TO DEVELOP, COMMERCIALIZE GLP-1R AGONIST PROGRAM IN CHINA, HK, AND OTHER COUNTRIES.VTV THERAPEUTICS INC SAYS WILL RECEIVE AN $8 MILLION UPFRONT PAYMENT AND IS ELIGIBLE FOR UP TO AN ADDITIONAL $75 MILLION IN MILESTONE PAYMENTS.  Full Article

VTv Therapeutics Entered Into Agreement With MacAndrews & Forbes
Wednesday, 6 Dec 2017 

Dec 6 (Reuters) - Vtv Therapeutics Inc ::VTV THERAPEUTICS SAYS ON DEC 5, CO ENTERED INTO A LETTER AGREEMENT WITH MACANDREWS & FORBES GROUP LLC - SEC FILING.VTV THERAPEUTICS INC - ENTERED AGREEMENT FOR INVESTOR'S COMMITMENT TO PURCHASE, CO'S CLASS A COMMON STOCK AT $4.38/SHARE.VTV THERAPEUTICS INC - AMOUNT OF COMMON STOCK THAT MAY BE PURCHASED BY INVESTOR PURSUANT TO LETTER AGREEMENT IS LIMITED TO $10.0 MILLION.  Full Article

vTv Therapeutics reports Q3 GAAP loss per share of $0.38
Thursday, 2 Nov 2017 

Nov 1 (Reuters) - Vtv Therapeutics Inc ::vTv Therapeutics reports third quarter 2017 financial and operational results.Q3 GAAP loss per share $0.38.Q3 earnings per share view $-0.41 -- Thomson Reuters I/B/E/S.Qtrly ‍non-GAAP net loss per fully exchanged share was $0.38​.Research and development expenses were $9.0 million in Q3 of 2017, compared to $9.6 million in Q2 of 2017​.  Full Article

vtv Therapeutics completes enrollment of phase 2 trial evaluating TTP273 for treatment of type 2 diabetes
Tuesday, 16 Aug 2016 

vtv Therapeutics Inc : vtv therapeutics completes enrollment of phase 2 trial evaluating TTP273 for treatment of type 2 diabetes .Topline results are expected late this year.  Full Article

Vtv Therapeutics Qtrly revenue $376,000
Friday, 13 May 2016 

Vtv Therapeutics Inc : Qtrly revenue $376,000 versus $50,000 . Qtrly loss per share $0.42 for class a common stock .Vtv therapeutics reports first quarter financial and operational results.  Full Article

BRIEF-Vtv Therapeutics, Reneo Pharmaceuticals Enter Licensing Agreement

* VTV THERAPEUTICS AND RENEO PHARMACEUTICALS ENTER LICENSING AGREEMENT FOR PPAR-DELTA PROGRAM